Empagliflozin reduces myocardial ketone utilization while preserving glucose utilization in diabetic hypertensive heart disease: A hyperpolarized 13 C magnetic resonance spectroscopy study-Reference-Cited by-同舟云学术

Empagliflozin reduces myocardial ketone utilization while preserving glucose utilization in diabetic hypertensive heart disease: A hyperpolarized 13 C magnetic resonance spectroscopy study

Published:2018-10-18 Issue:2 Volume:21 Page:357-365
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Abdurrachim Desiree¹,Teo Xing Qi¹,Woo Chern Chiuh¹,Chan Wei Xin¹,Lalic Janise¹,Lam Carolyn S. P.¹²,Lee Philip Teck Hock¹^ORCID

Affiliation:

1. Singapore Bioimaging Consortium, Agency for Science, Technology and Research; Singapore

2. National Heart Centre Singapore and Duke-National University of Singapore; Singapore

Funder

Asian neTwork for Translational Research and Cardiovascular Trials, ATTRaCT

A*STAR Biomedical Research Council

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.13536/fullpdf

Reference32 articles.

1. Diabetes and cardiovascular risk factors: the Framingham study;Kannel;Circulation,1979

2. Evaluating the cardiovascular safety of new medications for type 2 diabetes: time to reassess?;Smith;Diabetes Care,2016

3. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes;Zinman;N Engl J Med,2015

4. Myocardial fatty acid metabolism in health and disease;Lopaschuk;Physiol Rev,2010

5. Regulation of sarcolemmal transport of substrates in the healthy and diseased heart;Glatz;Cardiovasc Drugs Ther,2006

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SGLT2 Inhibition in Heart Failure: Clues to Cardiac Effects?;Cardiology in Review;2024-01-08

2. Searching for Effective Treatments in HFpEF: Implications for Modeling the Disease in Rodents;Pharmaceuticals;2023-10-12

3. Animal models of heart failure with preserved ejection fraction (HFpEF): from metabolic pathobiology to drug discovery;Acta Pharmacologica Sinica;2023-08-29

4. Assessment of Cardiac Energy Metabolism, Function, and Physiology in Patients With Heart Failure Taking Empagliflozin: The Randomized, Controlled EMPA-VISION Trial;Circulation;2023-05-30

5. Metabolic mechanisms in physiological and pathological cardiac hypertrophy: new paradigms and challenges;Nature Reviews Cardiology;2023-05-26